Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate.
Bioorg Med Chem Lett
; 27(4): 1099-1104, 2017 02 15.
Article
em En
| MEDLINE
| ID: mdl-28082036
ABSTRACT
Axl has been a target of interest in the oncology field for several years based on its role in various oncogenic processes. To date, no wild-type Axl crystal structure has been reported. Herein, we describe the structure-based optimization of a novel chemotype of Axl inhibitors, 1H-imidazole-2-carboxamide, using a mutated kinase homolog, Mer(I650M), as a crystallographic surrogate. Iterative optimization of the initial lead compound (1) led to compound (21), a selective and potent inhibitor of wild-type Axl. Compound (21) will serve as a useful compound for further in vivo studies.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Proteínas Proto-Oncogênicas
/
Receptores Proteína Tirosina Quinases
/
Inibidores de Proteínas Quinases
/
Imidazóis
/
Mutação
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article